Abstract
Objective. To determine the value of biomarkers in the diagnosis and monitoring of complicated course of acute pleural empyema. Materials and Methods. We analyzed the results of treatment of 426 patients with acute pleural empyema for the period 2008–2022. This study included patients (n = 64) with clinical and laboratory signs of systemic inflammatory response syndrome and clinically proven infection that complicated the course of pleural empyema – sepsis (group 1), and patients (n = 63) with acute pleural empyema without signs of a systemic infectious process – without established sepsis (group 2). Results. The results of the study allowed us to form an idea of the importance of biomarkers in the diagnosis and monitoring of the complicated course of acute pleural empyema in different periods of complex treatment. Conclusions. The use of additional biomarkers reflecting specific pathological processes may become an important tool for making clinical decisions regarding the management of patients with sepsis.

This publication has 9 references indexed in Scilit: